First ever Tesla diner and drive-in theater opens in California
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
New Lizzo song pokes at Sydney Sweeney's American Eagle jeans mess
Sydney Sweeney might be all buttoned up regarding her controversial American Eagle jeans/genes ad campaign, but Lizzo isn't ready to let the scandal die down just yet. For the rare few who missed the internet's ire over the 'Euphoria' star's jeans ads that launched late last month, many took the 'Sydney Sweeney Has Great Jeans' slogan as a nod to Nazi-era eugenics. Grammy winner Lizzo, 37, shared a clip from the 'I'm Goin' In Till October' music video on Wednesday, less than a week after American Eagle broke their silence on the denim mess. 'No kizzy, he ain't got no business being with me/ Fat a– pretty face with the t—s,' sings the 'Juice' pop star, real name Melissa Viviane Jefferson. 'B—, I got good jeans like I'm Sydney.' Though some might assume the winking lyric should be spelled 'genes,' Lizzo hinted earlier this week at being inspired by the scandal, when she previewed the new track as she sported an all-denim get-up, channeling 27-year-old Sweeney. The video, captioned 'Lizzo's got Good Jeans,' began with a pundit slamming the 'woke agenda' and the response to the Emmy nominee. It was a since-deleted commercial that courted controversy as the 'Anyone But You' star tells consumers, genes, or jeans, are 'passed down from parents to offspring, determining traits like hair color, personality and even eye color.' The blue-eyed, blonde bombshell — whose own look the internet quickly equated to the Aryan aesthetic favored by Adolf Hitler — then proclaims that her 'jeans are blue.' American Eagle on Friday insisted the campaign 'is and always was about the jeans' and that the retailer would 'continue to celebrate how everyone wears their AE jeans with confidence, their way. Great jeans look good on everyone.' Lizzo's tongue-in-cheek move comes two years after her own reputation took a hit in August 2023, when her former dancers filed a lawsuit accusing the body positive songstress of racial and sexual harassment and weight-shaming. A September 2023 lawsuit filed by Lizzo's former wardrobe assistant was dropped in December 2024.
Yahoo
24 minutes ago
- Yahoo
Union Pacific Celebrates Its Newest Intermodal Terminal in the Heart of America
The Kansas City Intermodal Terminal provides regional shippers seamless access to growing markets KANSAS CITY, Kan., August 07, 2025--(BUSINESS WIRE)--Union Pacific Railroad celebrated the grand opening of its newest intermodal terminal today in Kansas City, Kansas. This is the fourth intermodal facility Union Pacific has opened since 2021 as part of its ongoing commitment to quickly meet customers' needs and grow the railroad's intermodal footprint. The Kansas City Intermodal Terminal (KCIT) is strategically located near several key highway and interstate arteries that will provide shippers seamless access to Union Pacific's intermodal rail network, with fast, truck-competitive transit times. "This new terminal reflects our commitment to building for the future and providing our customers with convenient and cost-effective access to the U.S. supply chain," said Kenny Rocker, executive vice president-Marketing and Sales at Union Pacific Railroad. "Our customers want faster, more reliable freight options and this terminal delivers." The terminal will serve both domestic and international containerized shipments of grains, consumer goods, refrigerated products, and auto parts in the Midwest region, and will help to convert more truck traffic to rail, which will reduce congestion on the nation's highways and lower greenhouse gas emissions. The new terminal also will significantly increase Union Pacific's local capacity with room available for future growth. It includes two new paved parking lots, additional working tracks for peak efficiency and will feature precision gate technology, providing truckers with automatic entry and exit. Union Pacific also announced it will shift its KCIT domestic service from the Intermodal Container Transfer Facility (ICTF) terminal in Long Beach, California, to the City of Industry terminal in Southern California. Domestic units moving to KCIT will now benefit from Union Pacific's expedited premium network six days a week, offering a more than 25% faster journey and up to 25 hours in savings compared to current industry options, with just over 2.5 days transit. Making the change to City of Industry will complement the KCIT terminal and allow for expanded market access, efficient drayage management and enhanced logistics planning. Units originating in Kansas City will continue to utilize the existing expedited premium train to the City of Industry terminal. ABOUT UNION PACIFIC Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at View source version on Contacts MEDIA CONTACT:Kristen South, Corporate Communications & Media Relationskmsouth@ (402) 544-3435 Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti's Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad. Scannell brings a wealth of experience in the medical device market having served in leadership positions with Stryker Corporation for over thirty years. He advanced from sales and marketing to executive leadership roles highlighted by ten years as Group President of MedSurg & Neurotechnology and three years as President and COO of Stryker. He was responsible for assisting in the selection and development of the strategies and talent that delivered over the last three decades and continues to deliver outstanding results today. Scannell is currently scaling MedTech businesses with his involvement as board representative and chair for multiple public and private companies, with the majority offering interaction with neurosciences and neurosurgeons. In his role as Chair, he will assist with formulating strategic plans and providing oversight while serving as a sounding board for management. Longeviti established a strategic capital partnership with Soleus Capital, a healthcare investment firm based in Greenwich, CT. The firm, which invests in the innovative areas of life sciences including medical technology, biotechnology, diagnostics, and life science tools, has committed $10 million in structured financing to fund key strategic priorities for Longeviti. With this capital, Longeviti is poised to accelerate talent acquisition needs, continued development of its groundbreaking neurotechnology platforms, expand its market presence, and continue delivering life-changing innovations that enhance patient care. 'Tim's appointment as Chair of the Board brings world-class leadership and unmatched insight from decades of success in building, and leading, high-performing MedTech companies. His experience will be instrumental as we sharpen our strategy and deepen our impact in neurotechnology. Coupled with the $10 million capital infusion from Soleus Capital, Longeviti now has the momentum to grow our team, advance critical research, and accelerate the development and delivery of life-changing solutions for patients with complex brain disorders,' shared Jesse Christopher, Co-Founder and CEO, Longeviti Neuro Solutions. 'I easily said 'yes' to joining the Board of Directors for Longeviti, mainly because of the talent. I've known several of Longeviti's leaders for years, and admire their tenacity, persistence, and goals to make an instrumental difference in the neuro industry. Longeviti's technology is revolutionary and will support the advancement of patient care in neurosciences, creating a value for the industry, our shareholders, and employees,' said Tim Scannell, Chair, Board of Directors, Longeviti Neuro Solutions and former President and COO, Stryker. 'I'm honored to share my experiences and opinions to support the success of Longeviti.' 'We were introduced to Longeviti by a respected key opinion leader who had firsthand experience using their innovative products in clinical practice. We were deeply impressed by the company's mission and strong operating results,' shared Ben Lund, Partner, Soleus Capital. 'It was clear to us that with the right capital support, Longeviti could scale its team, reach more clinicians and patients, and amplify its impact on those living with complex brain disorders. We are proud to be part of that growth.' About Longeviti Neuro Solutions ( Longeviti Neuro Solutions is a leading innovator in functional neurotechnology, dedicated to developing advanced solutions that improve the lives of patients with neurological conditions during and after surgery, while also returning them to anatomical normalcy. The Baltimore-based company has full manufacturing, packaging, designing, and sterilizing capabilities in-house with multiple FDA clearances, successful FDA audits, and ISO 13485 Certifications. Longeviti has 50 worldwide patents to date. Longeviti's mission is to develop innovative platform solutions for complex brain surgery. Its products are currently approved for use in over 120 hospitals across the globe. To date, Longeviti neurosurgical implants have helped over 4,000 patients. About Soleus Capital ( Soleus Capital is a healthcare investment firm based in Greenwich, CT. Founded in 2018, the company currently has ~$2B in assets under management. Soleus partners with companies across three strategies – public equity, private equity and structured credit – and across each of the life sciences subsectors – biotechnology, medical technology, life science tools and diagnostics. Contact: Nicole Halsey/Natalie Van Buskirk Polished Nichols PR & Marketing nicole@ natalie@ 410.952.2122/443.956.4765 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
